Please use this identifier to cite or link to this item: http://111.93.178.142:25000/jspui/handle/123456789/3037
Full metadata record
DC FieldValueLanguage
dc.contributor.authorG. Buela Priyanka-
dc.date.accessioned2026-04-15T09:13:01Z-
dc.date.available2026-04-15T09:13:01Z-
dc.date.issued2026-04-15-
dc.identifier.urihttp://111.93.178.142:25000/jspui/handle/123456789/3037-
dc.descriptionVo.38, No. 1,p164en_US
dc.description.abstractDesign and synthesis of new series of 4-amino-5-mercapto-4H-1,2,4-triazoles connected to coumarin ring and assessed for cytotoxity and the study of docking studies was done against MDA-MB-231 cell lines. Using substituted diols, a series of new coumarin linked 4-amino5-mercapto-4H-1,2,4-triazoles derivatives were synthesized from substituted diols. Moreover, the elucidation of the newly synthesized mercaptotriazole derivatives was achieved by spectral data. An MTT assay was employed to evaluate the antineoplastic activity against triple-negative breast cancer (TNBC) and the synthesized compounds demonstrated promising, potent, and innovative inhibitory effects, highlighting their potential for the development of new anticancer therapies. Compounds 8h, 8d, 8e, 8b, 8i, 8j and 8a exhibit high binding energies with target receptor MCL-1 enzyme of the MDA-MB231 cells, where remaining compounds exhibit good binding interactions with target protein. In silico Docking studies verified the uncompetitive inhibition of MCL-1 enzyme.en_US
dc.language.isoenen_US
dc.subjectCoumarinsen_US
dc.subjectMercaptotriazoleen_US
dc.subjectChromen-2-one derivativesen_US
dc.subjectMCL-1 enzymeen_US
dc.subjectAntineoplastic activityen_US
dc.subjectIn silico studiesen_US
dc.titleDesign, Synthesis, in silico Analysis and Pharmacological Evaluation of Coumarin Derived Mercaptotriazole Derivatives as MCL-1 Inhibitorsen_US
dc.typeOtheren_US
Appears in Collections:Vol38, No. 1, 2026

Files in This Item:
File Description SizeFormat 
1.pdfVo.38, No. 1,p164172.29 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.